JP Morgan Chase
TVTX icon

JP Morgan Chase’s Travere Therapeutics TVTX Stock Holding History

JP Morgan Chase’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.98M Sell
288,551
-33,064
-10% -$988K ﹤0.01% 2885
2025
Q4 		$12.3M Sell
321,615
-172,226
-35% -$5.6M ﹤0.01% 2503
2025
Q3 		$11.8M Sell
493,841
-277,989
-36% -$5.23M ﹤0.01% 2579
2025
Q2 		$11.4M Buy
771,830
+156,535
+25% +$2.59M ﹤0.01% 2435
2025
Q1 		$11M Buy
615,295
+3,637
+0.6% +$73.8K ﹤0.01% 2450
2024
Q4 		$10.7M Sell
611,658
-136,900
-18% -$2.42M ﹤0.01% 2634
2024
Q3 		$10.5M Sell
748,558
-36,737
-5% -$383K ﹤0.01% 2564
2024
Q2 		$6.46M Buy
785,295
+436,135
+125% +$2.94M ﹤0.01% 2832
2024
Q1 		$2.69M Sell
349,160
-42,556
-11% -$359K ﹤0.01% 3599
2023
Q4 		$3.52M Sell
391,716
-91,995
-19% -$670K ﹤0.01% 3401
2023
Q3 		$4.32M Sell
483,711
-245,697
-34% -$3.47M ﹤0.01% 2942
2023
Q2 		$11.2M Sell
729,408
-404,743
-36% -$7.36M ﹤0.01% 2199
2023
Q1 		$25.5M Sell
1,134,151
-88,807
-7% -$1.89M ﹤0.01% 1488
2022
Q4 		$25.7M Buy
1,222,958
+165,955
+16% +$3.52M ﹤0.01% 1471
2022
Q3 		$26M Sell
1,057,003
-40,934
-4% -$1.06M ﹤0.01% 1401
2022
Q2 		$26.6M Buy
1,097,937
+13,369
+1% +$336K ﹤0.01% 1402
2022
Q1 		$27.9M Sell
1,084,568
-49,941
-4% -$1.33M ﹤0.01% 1512
2021
Q4 		$35.2M Buy
1,134,509
+158,369
+16% +$4.46M ﹤0.01% 1401
2021
Q3 		$23.7M Sell
976,140
-80,384
-8% -$1.48M ﹤0.01% 1624
2021
Q2 		$15.4M Buy
1,056,524
+1,027,538
+3,545% +$20.3M ﹤0.01% 2056
2021
Q1 		$724K Sell
28,986
-6,923
-19% -$191K ﹤0.01% 4447
2020
Q4 		$979K Buy
35,909
+11,232
+46% +$262K ﹤0.01% 3983
2020
Q3 		$460K Buy
24,677
+5,237
+27% +$102K ﹤0.01% 4022
2020
Q2 		$397K Sell
19,440
-81
-0.4% -$1.29K ﹤0.01% 3946
2020
Q1 		$285K Sell
19,521
-1,153
-6% -$17.3K ﹤0.01% 4119
2019
Q4 		$294K Buy
20,674
+2,462
+14% +$31.4K ﹤0.01% 4523
2019
Q3 		$211K Buy
18,212
+1,040
+6% +$17.2K ﹤0.01% 4609
2019
Q2 		$344K Buy
17,172
+2,815
+20% +$55.6K ﹤0.01% 4410
2019
Q1 		$325K Buy
14,357
+74
+0.5% +$1.64K ﹤0.01% 4410
2018
Q4 		$324K Buy
14,283
+1,541
+12% +$38.3K ﹤0.01% 4355
2018
Q3 		$366K Sell
12,742
-51,231
-80% -$1.46M ﹤0.01% 4427
2018
Q2 		$1.74M Sell
63,973
-60,271
-49% -$1.61M ﹤0.01% 3509
2018
Q1 		$2.78M Sell
124,244
-9,993
-7% -$238K ﹤0.01% 3040
2017
Q4 		$2.83M Buy
134,237
+2,105
+2% +$48.1K ﹤0.01% 3103
2017
Q3 		$3.27M Sell
132,132
-5,394
-4% -$119K ﹤0.01% 2872
2017
Q2 		$2.67M Buy
137,526
+5,674
+4% +$103K ﹤0.01% 2873
2017
Q1 		$2.43M Buy
131,852
+130,921
+14,062% +$2.56M ﹤0.01% 2926
2016
Q4 		$18K Buy
+931
New +$19K ﹤0.01% 4724
2016
Q3 		– Sell
-23
Closed – – 4813
2016
Q2 		$0 Hold
23
– – ﹤0.01% 4957
2016
Q1 		$0 Sell
23
-1,638
-99% -$24.8K ﹤0.01% 4949
2015
Q4 		$32K Buy
+1,661
New +$33.2K ﹤0.01% 3996

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's TVTX Position: Q1 2026 in Review

JP Morgan Chase reduced its Travere Therapeutics (TVTX) stake by 10% in Q1 2026, selling an estimated $988K and leaving 288,551 shares worth $7.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

JP Morgan Chase first reported a position in TVTX in Q4 2015 and has held it in 41 quarters since. The position peaked at $35.2M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • JP Morgan Chase held 288,551 shares of Travere Therapeutics worth $7.98M as of Q1 2026.
  • JP Morgan Chase sold 33,064 Travere Therapeutics shares in Q1 2026, an estimated $988K.
  • Travere Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2885 holding.
  • JP Morgan Chase first reported a position in Travere Therapeutics in Q4 2015 and has held it in 41 quarters since.
  • JP Morgan Chase's Travere Therapeutics position peaked at $35.2M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.